摘要
目的观察NRL-001内生场热疗系统热疗化疗联合化疗治疗原发性肝癌的近期疗效,生存率及毒副反应。方法46例原发性肝癌患者随机分成治疗组与对照组。治疗组22例,应用羟基喜树碱(HCPT)、5-氟脲嘧啶(5-Fu)/甲酰四氢叶酸钙(CF),联合化疗,同时给予热疗。对照组24例,单纯给予HCPT、5-Fu/CF,联合化疗。结果治疗组与对照组的有效率分别为59.0%与29.1%,差异显著,P<0.05。中位生存期分别为14个月及8个月,1年生存率分别为;68.1%及33.3%,差异显著,2年生存率分别为:27.2%,4.1%,差异显著,P<0.05。毒副反应较轻,主要为Ⅰ、Ⅱ度的骨髓抑制及消化道反应,偶有发热及高血压,且治疗组低于对照组,差异无显著性。结论热疗联合HCPT、5-Fu/CF化疗,可增强化疗疗效,提高生存率、减轻化疗的毒付作用,安全可靠,值得临床推广使用。
[objective] To investigate the therapy effect, survival and side effects of chemotherapy combined with hyperthermia with NRL-001 endogenetic field tumor hyperthermia system in treatment of primary hepatic carcinoma （HPC）. [Methods] 46 patients with HPC were rondomlydivided into two groups. The observed group 22 patients, were treated with hydroxycamptothecin （HCPT）, 5-fluorouracil （5-FU）, calcium folinate（CF） and combined with hyperthermia. The control group 24 patients, were treated with the same drugs except hyperthermia. [Results] The efficacy were 59.0% and 29.1% in the observed grorp and the control group respectively. There was significant difference between them （P〈0.05）. The average life span were 14 months and 8 months, the survival in 1 and 2 years were 68.1%, 33.3% and 27.2%, 4.1% respectively （P 〈0.05）. The side effects were httle and the main side effects included myeosuppression（Ⅰ-Ⅱ degree）, gastrointestinal reactions, and fever. And the side effects in the observed group was less than the control group. [Conclusion] The treatment of chemotherapy combined with hyperthermia can enhance the therapy effect and survival, reduce the side effects, which was a safe and effective treatment.
出处
《中国现代医学杂志》
CAS
CSCD
北大核心
2006年第9期1414-1416,共3页
China Journal of Modern Medicine
关键词
热疗
联合化疗
羟基喜树碱
原发性肝癌
内生场热疗
hyperthermia
chemotherapy
hydrxycamptotherin
primary hepatic carcinoma（HPC）
